Overview
Switzerland's bone healing tech firm reported 72% total medical device revenue growth in 2025
Company achieved first-ever net profit of USD 2.6 million
Company expects at least 35% sales growth in 2026
Outlook
Kuros expects at least 35% sales growth in 2026 with adjusted EBITDA margin around 14%
Company anticipates 2028 sales of USD 300 to 330 mln with adjusted EBITDA margin of 20%
Kuros sees growth driven by MagnetOs adoption and market penetration in U.S. and Europe
Result Drivers
MAGNETOS SALES - Direct MagnetOs sales rose by 71% to USD 143.9 mln, significantly contributing to overall revenue growth
MARKET EXPANSION - Kuros expanded into the extremities market, supported by a dedicated commercial team and clinical trials
NEW PRODUCT LAUNCHES - FDA clearance and launch of MagnetOs MIS Delivery System supported minimally invasive surgeries
Company press release: ID:nGNX3zFzYw
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Total Medical Device Revenue | $146.06 mln | ||
FY Operating Income | $8.95 mln |
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Kuros Biosciences AG is CHF36.50, about 37.3% above its March 9 closing price of CHF26.58
The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 95 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)